Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC).
Šutić M, Motzek A, Bubanović G, Linke M, Sabol I, Vugrek O, Ozretić P, Brčić L, Seiwerth S, Debeljak Ž, Jakovčević A, Janevski Z, Stančić-Rokotov D, Vukić-Dugac A, Jakopović M, Samaržija M, Zechner U, Knežević J.
Šutić M, et al. Among authors: zechner u.
Transl Lung Cancer Res. 2019 Dec;8(6):1000-1015. doi: 10.21037/tlcr.2019.12.08.
Transl Lung Cancer Res. 2019.
PMID: 32010578
Free PMC article.